William Blair analyst Steven Lichtman initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and no price target The company has done a good job of “de-risking” 2026 estimates by accounting for potential disruption, the analyst tells investors in a research note. The firm wants to monitor Zimmer’s execution on its com mercial changes in the U.S. before recommending the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet’s New Stemless Shoulder Study Signals Strategic Push in Joint Reconstruction
- Zimmer Biomet price target lowered to $100 from $104 at Barclays
- Zimmer Biomet participates in a conference call with JPMorgan
- Zimmer Biomet price target raised to $89 from $86 at UBS
- Zimmer Biomet price target raised to $98 from $94 at Citi